journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Drug Monitoring

journal
https://www.readbyqxmd.com/read/28489727/pharmacology-of-thiopurine-therapy-in-inflammatory-bowel-disease-and-complete-blood-cell-count-outcomes-a-five-year-database-study
#1
Berrie Meijer, Abraham J Wilhelm, Chris Jj Mulder, Gerd Bouma, Adriaan A van Bodegraven, Nanne Kh de Boer
BACKGROUND: Thiopurines Are The Prerequisite For Immunomodulation In Inflammatory Bowel disease (IBD) therapy. When administered in high (oncological) dose, thiopurine metabolites act as purine antagonists, causing DNA-strand breakage and myelotoxicity. In lower IBD dosages, the mode of action is primarily restricted to anti-inflammatory effects. Then, myelosuppression and hepatotoxicity are the most common adverse events of thiopurines. The aim of this study was to assess the effect of thiopurine metabolites on hematologic and hepatic parameters and to determine which patient characteristics are related to generation of thiopurine metabolites...
May 6, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28486309/rationale-for-therapeutic-drug-monitoring-of-biopharmaceuticals-in-inflammatory-diseases
#2
Gilles Paintaud, Christophe Passot, David Ternant, Bertolotto Antonio, Theodora Bejan-Angoulvant, Dora Pascual-Salcedo, Denis Mulleman
Biopharmaceuticals bring together a number of specific characteristics as compared with other drugs. However, as done for most drugs, an individual adjustment of their dose may be necessary. Similar to "chemical" drugs, biopharmaceuticals used in immuno-inflammatory diseases have a rather narrow therapeutic range, lack good early clinical or biological marker of response, have variable pharmacokinetics, and their serum concentration are most often related with response. Monoclonal antibodies (mAbs) have additional specific sources of pharmacokinetic variability...
May 5, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28486308/effect-of-n-desalkylquetiapine-quetiapine-plasma-level-ratio-on-anxiety-and-depression-in-bipolar-disorder-a-prospective-observational-study
#3
C Rovera, M C Mauri, C Di Pace, S Paletta, A Reggiori, V Ciappolino, D Cattaneo, S Baldelli, E Clementi, A C Altamura
BACKGROUND: The aim of this study was to analyse the relationships between quetiapine and N-desalkylquetiapine plasma levels and clinical improvement, particularly, in regard to depressive and anxious symptoms and to hostility. METHODS: This was a prospective observational study that involved 37 outpatients diagnosed as having bipolar disorder I or II. All the patients were observed during a clinical acute and postacute phase. Patients were prescribed 50-800 mg of quetiapine...
May 5, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28520580/high-agreement-between-benchtop-and-point-of-care-dipcard-tests-for-ethyl-glucuronide
#4
Emily Leickly, Jordan Skalisky, Sterling McPherson, Michael F Orr, Michael G McDonell
No abstract text is available yet for this article.
May 4, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28463887/immunogenicity-of-therapeutic-antibodies-monitoring-anti-drug-antibodies-in-a-clinical-context
#5
Karien Bloem, Borja Hernández-Breijo, Ana Martínez-Feito, Theo Rispens
One of the factors that may impact drug levels of therapeutic antibodies in patients is immunogenicity, with potential loss of efficacy. Nowadays, many immunogenicity assays are available for testing anti-drug antibodies (ADA). In this paper, we discuss different types of immunogenicity assays and their clinical relevance in terms of drug tolerance, relation with PK, neutralizing antibodies, potential adverse events associated with ADA, and prediction of ADA production. Drug-tolerant assays can provide insight into the process of immunogenicity, but for clinical management, these assays do not necessarily outperform drug-sensitive assays...
April 29, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28379895/current-practice-of-therapeutic-drug-monitoring-of-biopharmaceuticals-in-spondyloarthritis
#6
Frédéric Medina, Chamaida Placensia, Philippe Goupille, Gilles Paintaud, Alejandro Balsa, Denis Mulleman
Treatment of spondyloarthritis (SpA) has greatly improved in the biopharmaceutical era. These compounds, primarily tumor necrosis factor (TNF) inhibitors, are effective, but some patients may show poor response, sometimes due to the presence of anti-drug antibodies (ADAs). In some instances, clinicians may increase or taper the dose, depending on the clinical response. Besides the current clinical practice, a tailored strategy based on drug monitoring is emerging as a way to improve the use of these drugs. However, the relevance of this therapeutic drug monitoring (TDM) of biopharmaceuticals for SpA is still unknown...
April 4, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28379894/current-practice-of-therapeutic-drug-monitoring-of-biopharmaceuticals-in-psoriasis-patients
#7
Caroline Hermans, Pedro Herranz, Siegfried Segaert, Ann Gils
The high prevalence of psoriasis and the high spending on pharmaceuticals motivate a more evidence-based and cost-effective usage of biopharmaceuticals. A growing body of evidence exists that the implementation of therapeutic drug monitoring (TDM) for biopharmaceuticals in psoriasis patients optimizes patient management and clinical outcome and enhances their efficacy. Therefore, the aim of this review is to give an overview of the literature on TDM of biopharmaceuticals in the treatment of psoriasis and to provide the useful information to dermatologists to improve health care in psoriasis patients...
April 4, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28328761/drug-efficacy-monitoring-in-pharmacotherapy-of-multiple-sclerosis-with-biological-agents
#8
M Caldano, W Raoul, T Rispens, A Bertolotto
Multiple Sclerosis (MS) is a heterogeneous disease. Although several EMA approved Disease Modifying Treatments including biopharmaceuticals are available, their efficacy is limited and a certain percentage of patients are always non-responsive. Drug Efficacy Monitoring is an important tool to identify these non-responsive patients early on. Currently, Detection of Anti-Drug Antibodies and quantification of Biological Activity are used as methods of efficacy monitoring for Interferon beta (IFNβ) and Natalizumab (NAT) therapies...
March 22, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28328760/current-practice-for-therapeutic-drug-monitoring-of-biopharmaceuticals-in-inflammatory-bowel-disease
#9
Iris Detrez, Thomas Van Stappen, María Dolores Martín Arranz, Kostas Papamichael, Ann Gils
Since the late nineties, biopharmaceuticals targeting tumor necrosis factor α have revolutionized the treatment of moderately to severely active inflammatory bowel disease. The robust efficacy witnessed in many patients stands in stark contrast with the observation of a proportion of patients who fail to respond or who lose response over time. Therapeutic drug monitoring has been proposed as a means to understand and respond to the variability in clinical response and remission. Various treatment algorithms have been proposed, but optimal use of these measurements in daily practice awaits additional prospective validation trials...
March 22, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28490050/is-trough-concentration-of-vancomycin-predictive-of-the-area-under-the-curve-a-commentary
#10
Anna-Karin Hamberg, Ron Keizer
No abstract text is available yet for this article.
June 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28490049/comparison-of-plasma-saliva-and-hair-levetiracetam-concentrations
#11
Katarzyna Karaś-Ruszczyk, Julita Kuczyńska, Halina Sienkiewicz-Jarosz, Iwona Kurkowska-Jastrzębska, Przemyslaw Bienkowski, Magdalena Restel, Jerzy Samochowiec, Pawel Mierzejewski
BACKGROUND: Previous findings revealed high correlations between serum/plasma and saliva levetiracetam concentrations, indicating saliva as an alternative matrix for monitoring levetiracetam therapy. Levetiracetam concentration in the hair, which could reflect long-term drug exposure and patients' compliance, has not been systematically tested, as yet. The aim of this study was to determine the correlation between plasma, saliva, and hair levetiracetam concentrations in 47 patients with epilepsy...
June 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28490048/simultaneous-determination-of-imatinib-dasatinib-and-nilotinib-by-liquid-chromatography-tandem-mass-spectrometry-and-its-application-to-therapeutic-drug-monitoring
#12
Aneta Wojnicz, Beatriz Colom-Fernández, Juan L Steegmann, Cecilia Muñoz-Calleja, Francisco Abad-Santos, Ana Ruiz-Nuño
BACKGROUND: Imatinib, dasatinib, and nilotinib are tyrosine kinase inhibitors (TKIs) used as first-line treatment of chronic myeloid leukemia. Therapeutic drug monitoring is important to achieve treatment efficacy in the case of imatinib and nilotinib, and to control toxicity in the case of dasatinib. New high-sensitivity methods to monitor those drugs are needed, especially for dasatinib. Thus, a simple method to determine plasma levels of imatinib, dasatinib, and nilotinib for application in clinical practice was developed...
June 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28490047/development-and-validation-of-an-lc-ms-ms-method-for-the-simultaneous-quantification-of-abiraterone-enzalutamide-and-their-major-metabolites-in-human-plasma
#13
Merel van Nuland, M J X Hillebrand, H Rosing, J H M Schellens, J H Beijnen
BACKGROUND: Abiraterone acetate and enzalutamide are 2 novel drugs for the treatment of metastatic castration-resistant prostate cancer. The metabolism of these drugs is extensive. Major metabolites are N-desmethyl enzalutamide, enzalutamide carboxylic acid, abiraterone N-oxide sulfate, and abiraterone sulfate; of which N-desmethyl enzalutamide is reported to possess antiandrogen capacities. A liquid chromatography-tandem mass spectrometry method for simultaneous quantification of abiraterone, enzalutamide, and the main metabolites has been developed and validated to support therapeutic drug monitoring...
June 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28490046/rapid-homogeneous-immunoassay-to-quantify-gemcitabine-in-plasma-for-therapeutic-drug-monitoring
#14
Daniel Kozo, Matt W Ross, Justin Jarrah, Michael Barrett, Rebecca L Harney, Jodi B Courtney, Irina Baburina, Julianne L Holleran, Jan H Beumer, Godefridus J Peters, Richard J Honeywell, Salvatore J Salamone
BACKGROUND: Gemcitabine (2',2'-difluoro-2'-deoxycytidine) is a nucleoside analog used as a single agent and in combination regimens for the treatment of a variety of solid tumors. Several studies have shown a relationship between gemcitabine peak plasma concentration (Cmax) and hematological toxicity. An immunoassay for gemcitabine in plasma was developed and validated to facilitate therapeutic drug monitoring (TDM) by providing an economical, robust method for automated chemistry analyzers...
June 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28445212/plasma-concentration-of-itraconazole-in-patients-with-hematologic-malignancies-treated-with-itraconazole-oral-solution
#15
Atsushi Marumo, Shuichi Miyawaki, Naoaki Dan, Ken Ishiyama
BACKGROUND: The prophylactic administration of itraconazole (ITCZ) is effective for preventing mycotic infections during chemotherapy in patients with hematologic malignancies. However, fungal infections can occur when the ITCZ does not reach an effective concentration. METHODS: We conducted a prospective study to monitor the plasma concentration of ITCZ and hydroxyl-ITCZ (OH-ITCZ) weekly and to verify whether the day 3 plasma concentration of ITCZ could predict the subsequent acquisition of an effective plasma concentration...
June 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28437285/monitoring-protein-unbound-valproic-acid-serum-concentrations-in-clinical-practice
#16
Eveline Wallenburg, Bas Klok, Karin de Jong, Monique de Maat, Nielka van Erp, Sonja Stalpers-Konijnenburg, Guus Essink, Matthijs van Luin
BACKGROUND: Valproic acid (VPA) is an effective antiepileptic drug and mood stabilizer. A key characteristic of VPA is its high and saturable protein binding at higher concentrations. Although the unbound concentration of VPA is responsible for its pharmacological activity, total drug concentrations are monitored in routine clinical practice. Therapeutic drug monitoring (TDM) of unbound VPA is recommended for specific clinical situations. The goal of this study was to evaluate TDM requests for unbound VPA in clinical practice...
June 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28437284/a-retrospective-study-on-mycophenolic-acid-drug-interactions-effect-of-prednisone-sirolimus-and-tacrolimus-with-mpa
#17
Ana C Alvarez-Elías, Elisa C Yoo, Ekaterina K Todorova, Ram N Singh, Guido Filler
Mycophenolic acid (MPA), the active compound of mycophenolate mofetil (MMF), is widely used as an antirejection drug after renal transplantation. There is growing evidence supporting the notion that there is substantial variability in the intra- and interpatient exposure to MPA. Drug interactions involving MPA with tacrolimus, steroids, and sirolimus have been understudied. The objective of this study was to determine the relationship between MPA, steroids, tacrolimus, and sirolimus. MPA trough concentrations from 37 pediatric renal transplant recipients (mean age 7...
June 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28399040/a-new-enzyme-linked-immunosorbent-assay-for-a-total-anti-t-lymphocyte-globulin-determination-development-analytical-validation-and-clinical-applications
#18
Michela Montagna, Giorgio La Nasa, Maria E Bernardo, Eugenia Piras, Maria A Avanzini, Mario Regazzi, Franco Locatelli
BACKGROUND: Anti-T lymphocyte globulin (ATLG) modulates the alloreactivity of T lymphocytes, reducing the risk of immunological posttransplant complications, in particular rejection and graft-versus-host disease, after allogeneic hematopoietic stem cell transplantation (HSCT). We developed and validated a new enzyme-linked immunosorbent assay (ELISA) method to measure serum levels of total ATLG and evaluate the pharmacokinetics (PK) of the drug in children with β-Thalassemia, receiving allogeneic HSCT...
June 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28383317/therapeutic-drug-monitoring-in-children-and-adolescents-under-pharmacotherapy-with-olanzapine-in-daily-clinical-practice
#19
Stefanie Fekete, Christoph Wewetzer, Claudia Mehler-Wex, Kristian Holtkamp, Rainer Burger, Susanne Reichert, Regina Taurines, Marcel Romanos, Manfred Gerlach, Karin Egberts
BACKGROUND: The relationship between daily dose, serum concentrations, and clinical outcomes of olanzapine as well as the influencing factors thereof in children and adolescents treated for different psychiatric disorders were investigated in daily clinical practice. In addition, it was examined whether the current recommended therapeutic range (TR) for adult patients with psychotic disorders is valid for minors. METHODS: The Competence Network for Therapeutic Drug Monitoring (www...
June 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/28346313/population-pharmacokinetics-of-gemcitabine-and-dfdu-in-pancreatic-cancer-patients-using-an-optimal-design-sparse-sampling-approach
#20
Cindy Serdjebi, Florence Gattacceca, Jean-François Seitz, Francine Fein, Johan Gagnière, Eric François, Abakar Abakar-Mahamat, Gael Deplanque, Madani Rachid, Bruno Lacarelle, Joseph Ciccolini, Laetitia Dahan
BACKGROUND: Gemcitabine remains a pillar in pancreatic cancer treatment. However, toxicities are frequently observed. Dose adjustment based on therapeutic drug monitoring might help decrease the occurrence of toxicities. In this context, this work aims at describing the pharmacokinetics (PK) of gemcitabine and its metabolite dFdU in pancreatic cancer patients and at identifying the main sources of their PK variability using a population PK approach, despite a sparse sampled-population and heterogeneous administration and sampling protocols...
June 2017: Therapeutic Drug Monitoring
journal
journal
27774
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"